Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 10/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1226849 | 1.00 | GRIN2B (0.34) | GRIN2BGRIN1ITGB3ITGA2BKMT2A | |
| SCHEMBL12385571 | 1.00 | GRIN2B (0.34) | GRIN2BGRIN1ITGB3ITGA2BKMT2A | |
| SCHEMBL1226830 | 0.83 | S1PR1 (0.42) | GRIN2BGRIN1ITGB3ITGA2BKMT2A | |
| SCHEMBL1226827 | 0.83 | S1PR1 (0.42) | GRIN2BGRIN1ITGB3ITGA2BKMT2A | |
| SCHEMBL409067 | 0.82 | SIRT2 (0.41) | S1PR1S1PR3SIRT2SIRT1GAA | |
| SCHEMBL410000 | 0.82 | SIRT2 (0.41) | S1PR1S1PR3SIRT2SIRT1GAA | |
| SCHEMBL409928 | 0.82 | SIRT2 (0.41) | S1PR1S1PR3SIRT2SIRT1GAA | |
| SCHEMBL1226213 | 0.81 | GRIN2B (0.49) | GRIN2BGRIN1GAA | |
| SCHEMBL12385570 | 0.79 | GRIN2B (0.38) | GRIN2BGRIN1 | |
| SCHEMBL1225761 | 0.76 | ALDH1A1 (0.52) | KMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | GRIN2B 1895/4885GRIN1 589/4885ITGB3 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.